In the case of Novartis AG v. Venkata Narayana Active Ingredients, the Madras High Court has provided clarity on the evidentiary requirements for invoking the Bolar exemption, marking a notable development in pharmaceutical patent law.
Clarifying the Bolar Exemption
The Madras High Court recently ruled in Novartis AG v. Venkata Narayana Active Ingredients, addressing the evidentiary burden required to invoke the Bolar exemption for regulatory approval concerning pharmaceutical exports. This decision is significant as it presents the first post-trial examination of such evidence in this context.
The court emphasized the necessity for manufacturers to provide clear and sufficient evidence that their activities fall under the Bolar exemption stipulated in Section 107A of the Patents Act. This exemption permits the use of a patented invention to obtain regulatory approval prior to the expiration of the patent.
Legal commentators note that while the court's approach aims to bring greater clarity to the evidentiary standards required, it may inadvertently impose burdens on manufacturers, thereby countering the exemption's original purpose. The ruling highlights the delicate balance between protecting patent rights and encouraging the availability of generic medications in the market.
This landmark ruling calls for careful attention from practitioners in the pharmaceutical sector. It underscores the need for robust compliance mechanisms for evidence handling while navigating the complexities of patent law in relation to regulatory processes.
Citations
- Novartis AG v. Venkata Narayana Active Ingredients (2026) Madras HC
